530 related articles for article (PubMed ID: 12796132)
1. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.
Sebkhi A; Strange JW; Phillips SC; Wharton J; Wilkins MR
Circulation; 2003 Jul; 107(25):3230-5. PubMed ID: 12796132
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
Zhao L; Mason NA; Strange JW; Walker H; Wilkins MR
Circulation; 2003 Jan; 107(2):234-7. PubMed ID: 12538421
[TBL] [Abstract][Full Text] [Related]
3. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.
Weimann J; Ullrich R; Hromi J; Fujino Y; Clark MW; Bloch KD; Zapol WM
Anesthesiology; 2000 Jun; 92(6):1702-12. PubMed ID: 10839922
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
7. Sildenafil inhibits hypoxia-induced pulmonary hypertension.
Zhao L; Mason NA; Morrell NW; Kojonazarov B; Sadykov A; Maripov A; Mirrakhimov MM; Aldashev A; Wilkins MR
Circulation; 2001 Jul; 104(4):424-8. PubMed ID: 11468204
[TBL] [Abstract][Full Text] [Related]
8. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial.
Ghofrani HA; Reichenberger F; Kohstall MG; Mrosek EH; Seeger T; Olschewski H; Seeger W; Grimminger F
Ann Intern Med; 2004 Aug; 141(3):169-77. PubMed ID: 15289213
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches to pulmonary hypertension in hemoglobinopathies: Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathy.
Derchi G; Forni GL
Ann N Y Acad Sci; 2005; 1054():471-5. PubMed ID: 16339700
[TBL] [Abstract][Full Text] [Related]
10. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
Baliga RS; Zhao L; Madhani M; Lopez-Torondel B; Visintin C; Selwood D; Wilkins MR; MacAllister RJ; Hobbs AJ
Am J Respir Crit Care Med; 2008 Oct; 178(8):861-9. PubMed ID: 18689467
[TBL] [Abstract][Full Text] [Related]
11. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
12. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
Rondelet B; Kerbaul F; Van Beneden R; Motte S; Fesler P; Hubloue I; Remmelink M; Brimioulle S; Salmon I; Ketelslegers JM; Naeije R
Circulation; 2004 Oct; 110(15):2220-5. PubMed ID: 15466636
[TBL] [Abstract][Full Text] [Related]
13. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb.
Jaillard S; Larrue B; Deruelle P; Delelis A; Rakza T; Butrous G; Storme L
Ann Thorac Surg; 2006 Mar; 81(3):935-42. PubMed ID: 16488698
[TBL] [Abstract][Full Text] [Related]
14. Antenatal sildenafil treatment attenuates pulmonary hypertension in experimental congenital diaphragmatic hernia.
Luong C; Rey-Perra J; Vadivel A; Gilmour G; Sauve Y; Koonen D; Walker D; Todd KG; Gressens P; Kassiri Z; Nadeem K; Morgan B; Eaton F; Dyck JR; Archer SL; Thébaud B
Circulation; 2011 May; 123(19):2120-31. PubMed ID: 21537000
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase type 5 and high altitude pulmonary hypertension.
Aldashev AA; Kojonazarov BK; Amatov TA; Sooronbaev TM; Mirrakhimov MM; Morrell NW; Wharton J; Wilkins MR
Thorax; 2005 Aug; 60(8):683-7. PubMed ID: 16061711
[TBL] [Abstract][Full Text] [Related]
16. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
17. Summaries for patients. Sildenafil increases exercise capacity in low-oxygen settings.
Ann Intern Med; 2004 Aug; 141(3):I12. PubMed ID: 15289233
[No Abstract] [Full Text] [Related]
18. Sildenafil in the treatment of pulmonary hypertension.
Barnett CF; Machado RF
Vasc Health Risk Manag; 2006; 2(4):411-22. PubMed ID: 17323595
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil reverses hypoxic pulmonary hypertension in highland and lowland newborn sheep.
Herrera EA; Ebensperger G; Krause BJ; Riquelme RA; Reyes RV; Capetillo M; González S; Parer JT; Llanos AJ
Pediatr Res; 2008 Feb; 63(2):169-75. PubMed ID: 18091352
[TBL] [Abstract][Full Text] [Related]
20. Sildenafil and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn piglets.
Binns-Loveman KM; Kaplowitz MR; Fike CD
Pediatr Pulmonol; 2005 Jul; 40(1):72-80. PubMed ID: 15880376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
